Company continued its strategy to focus and grow in niche segments for improved long term growth and margins. During the year, the Company divested its investments in Applied Clinical Intelligence and TAKE Business Cloud. It also made a strategic acquisition of Ecron Acunova in the last quarter of FY 2016 to further strengthen its offerings in life science domain. Acquisition of Ecron Acunova- Bodes well for company to increase its addressable market size Currently TAKE is providing functional services and software solutions related to clinical data management, regulatory compliance and drug safety, which constitutes just 35% of the pharma R&D; outsourcing. Prior to acquisition of EA, it had marginal presence in clinical trial studies, which is 60% of...